2012-10-05 17:24:18 - Recently published research from Global Markets Direct, "Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012", is now available at Fast Market Research

Global Markets Direct's, 'Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, H2 2012', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Post-polycythemia vera myelofibrosis (PPV-MF). Post-polycythemia vera myelofibrosis (PPV-MF) - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.


Full Report Details at
- www.fastmr.com/prod/468474_postpolycythemia_vera_myelofibrosis_p ..


Note*: Certain

sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Post-polycythemia vera myelofibrosis (PPV-MF).
* A review of the Post-polycythemia vera myelofibrosis (PPV-MF) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Post-polycythemia vera myelofibrosis (PPV-MF) pipeline on the basis of route of administration and molecule type.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Post-polycythemia vera myelofibrosis (PPV-MF).
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Post-polycythemia vera myelofibrosis (PPV-MF) pipeline depth and focus of Indication therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Post-polycythemia vera myelofibrosis (PPV-MF) Overview
Therapeutics Development
An Overview of Pipeline Products for Post-polycythemia vera myelofibrosis (PPV-MF)
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics under Development by Companies
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics - Products under Development by Companies
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics Development
Sanofi-Aventis
AstraZeneca PLC
Gilead Sciences, Inc.
YM BioSciences Inc.
Incyte Corporation
PharmaMar, S.A.
Post-polycythemia vera myelofibrosis (PPV-MF) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AZD-1480 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
momelotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ruxolitinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SAR-302503 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
plitidepsin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GS-6624 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
GC-1008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics - Drug Profile Updates
Post-polycythemia vera myelofibrosis (PPV-MF) Therapeutics - Dormant Products
Post-polycythemia vera myelofibrosis (PPV-MF) - Product Development Milestones
Featured News & Press Releases
Jun 04, 2012: Incyte Presents New Clinical Data Of Jakafi At ASCO 2012 Annual Meeting
May 16, 2012: Sanofi To Present Data On SAR302503 At 2012 American Society Of Clinical Oncology Annual Meeting
Apr 20, 2012: Incyte Announces EU Regulatory Milestone From Novartis For Ruxolitinib
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Post-polycythemia vera myelofibrosis (PPV-MF), H2 2012
Products under Development for Post-polycythemia vera myelofibrosis (PPV-MF) - Comparative Analysis, H2 2012
Number of Products under Development by Companies, H2 2012
Number of Products under Investigation by Universities/Institutes, H2 2012
Comparative Analysis by Late Stage Development, H2 2012
Comparative Analysis by Mid Clinical Stage Development, H2 2012
Comparative Analysis by Early Clinical Stage Development, H2 2012
Products under Development by Companies, H2 2012

Full Table of Contents is available at:
-- www.fastmr.com/catalog/product.aspx?productid=468474&dt=t

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information. View more research from Global Markets Direct at www.fastmr.com/catalog/publishers.aspx?pubid=1033

About Fast Market Research

Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.

For more information about these or related research reports, please visit our website at www.fastmr.com or call us at 1.800.844.8156.